Inclusive research and global access to medicines and diagnostics are vital to creating sustainable healthcare systems.
Addressing health impact for all is core to our mission to improve outcomes for patients. As an industry, we have an opportunity to identify and meet previously overlooked patient needs to create a healthier future for everyone. At Roche, we continue to increase patient representation in clinical trials and build more comprehensive healthcare data to develop medicines and diagnostic solutions.
Patients around the world face various challenges to better health – both in the medicines and diagnostic solutions they can access and the efficacy of those solutions. These challenges affect all patient populations and are impacted by factors like income, gender, ethnicity and socioeconomic position.
Better health outcomes for all requires a holistic solution. That’s why we consider health impact for all at every stage of the pharmaceutical and diagnostic product life cycle and throughout the patient journey.
We align both our strategic roadmaps and our commercial strategies toward supporting better health outcomes for all.
Inclusive research is vital to understanding how diseases, pharmaceuticals and diagnostics impact all patients.
Supported by external guidelines, we have built inclusive research principles into every part of our organisation – both functionally and throughout the development life cycle. This includes our early- and late-stage studies, our governance decisions within our clinical development process (e.g. in-study design), our operational systems (e.g. data-driven site selection focused on under-represented patient demographics) and with our global site alliance partnership (including in the U.S. and South Africa).
Increasing access to healthcare for all patients requires collaboration. Our work to improve health impact can only be successful if we engage and involve the communities who need support. We focus on building relationships with communities in need to improve their access to healthcare.
Communities in low- and lower-middle-income countries (LLMICs) are often underrepresented in medical research and lack sufficient access to healthcare. Roche is working to build relationships with these communities to help address these needs. For example, our long-standing partnership with
Collaborating with a broad spectrum of stakeholders is one of the most effective ways to create breakthroughs that improve health outcomes. Our Mission Leapfrog initiative is aimed at transforming patient wellbeing and population health in Asia by partnering with people across the region to support healthcare improvements.